Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
07:00am, Monday, 10'th Feb 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecu
Billionaire Stanley Druckenmiller says the AI boom could get much bigger – These are the stocks he owns
10:58am, Tuesday, 04'th Feb 2025
Stanley Druckenmiller is one of those legendary investors who are worth listening to and learning from.
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
07:00am, Monday, 03'rd Feb 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD n
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
10:05am, Saturday, 25'th Jan 2025
AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 stud
Natera to Present New Data at the 2025 ASCO GI Symposium
06:05pm, Tuesday, 21'st Jan 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studi
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
09:00am, Friday, 17'th Jan 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top heal
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
07:20pm, Sunday, 12'th Jan 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year end
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
08:15am, Thursday, 09'th Jan 2025
Decades away from his star-making turn at George Soros' Quantum Group of Funds, high-profile investor Stanley Druckenmiller stays well active in the stock-picking game with his Duquesne Family Office
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
09:00am, Tuesday, 07'th Jan 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in
Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
02:00pm, Friday, 03'rd Jan 2025
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering diverse investment opportunities and encouraging discussion among investors. Ready Capital Corporation's new senior notes
Natera: Poised For A Great Future But I'd Wait For A Pullback
05:50am, Tuesday, 31'st Dec 2024
Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. The company's competitive landscape is intense, with rivals
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
11:00am, Saturday, 21'st Dec 2024
Billionaire Stanley Druckenmiller might not be a household name like Warren Buffett, but he's one of the best investors of all time.
Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?
10:35am, Tuesday, 17'th Dec 2024
After reaching an important support level, Natera (NTRA) could be a good stock pick from a technical perspective. NTRA surpassed resistance at the 20-day moving average, suggesting a short-term bullis
Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics
08:00am, Tuesday, 17'th Dec 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGe
Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology
08:00am, Monday, 02'nd Dec 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) publis
